Cognitive & Neurological Peptides

Cognitive and neurological peptides encompass compounds that enhance brain function, protect neurons from damage, reduce anxiety, and improve sleep architecture. Many were developed in the former Soviet Union as part of a state-funded neuropeptide research programme and have decades of clinical use in Russia and Eastern Europe, though they remain largely unregulated in Western markets.

Semax is a synthetic heptapeptide analogue of the ACTH(4-10) sequence. Originally developed in Russia for stroke recovery and cognitive impairment, Semax has demonstrated rapid upregulation of BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor) following intranasal administration. These neurotrophin increases promote neuronal survival, synaptic plasticity, and the formation of new neural connections. Users in nootropic communities report enhanced focus, mental clarity, and working memory — effects consistent with its BDNF mechanism. It is approved in Russia as a medicine (Semax nasal spray).

Selank is an anxiolytic neuropeptide analogue of tuftsin, also developed in Russia and approved as a medicine for anxiety and phobia treatment. Its primary mechanism involves modulation of the GABAergic system, similar in outcome to benzodiazepines but through a different pathway and without the sedation or dependence liability. Selank also inhibits enkephalin-degrading enzymes, potentially extending the calming effects of endogenous opioid peptides. The Semax + Selank combination addresses the common challenge of nootropics: cognitive stimulation without anxiety amplification.

DSIP (Delta Sleep-Inducing Peptide) is a nonapeptide isolated from rabbit brain in 1974. As its name indicates, it promotes delta-wave (slow-wave) sleep — the deepest and most restorative stage of the sleep cycle. Delta sleep is critical for GH secretion, memory consolidation, and neural repair. DSIP has also been researched for its effects on stress reactivity and cortisol modulation.

Dihexa is a more recently characterised peptide (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) that has demonstrated extraordinary potency for synaptic facilitation in preclinical models — reported to be seven orders of magnitude more potent than BDNF at promoting the formation of new synaptic connections. Early animal data suggests significant cognitive enhancement potential, but human safety data is minimal.

In the UK, these peptides are unregulated research chemicals. Semax and Selank have an established safety record from Russian clinical practice. Researchers interested in cognitive peptides should be aware that intranasal administration carries different pharmacokinetic considerations than injectable routes.